Oruka Therapeutics NASDAQ:ORKA reported insider activity on March 2, 2026, when Chief Operating Officer Laura Lee Sandler sold a total of 5,000 shares of common stock for aggregate proceeds of $167,821. The disposals were carried out in two separate transactions with execution prices spanning from $32.66 to $34.33 per share.
The first tranche comprised 2,325 shares sold at a weighted average price of $33.2843, with individual executions priced between $32.66 and $33.64. The second tranche consisted of 2,675 shares sold at a weighted average price of $33.8077, with sale prices ranging from $33.66 to $34.33.
On the same date, Sandler exercised employee warrants to acquire 5,000 shares at an exercise price of $7.80 per share, representing a cash outlay of $39,000. Those warrants are part of an employee warrant plan and carry an expiration date of July 14, 2034. The warrants vest in a phased schedule - 1/4 of the underlying shares vested on April 3, 2025, with the remaining shares vesting at a rate of 1/48 of the underlying shares each month beginning April 3, 2025.
After completing the sales and the warrant exercise, Sandler directly holds 237,584 shares of Oruka Therapeutics. The dispositions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan that Sandler established on September 19, 2025.
Oruka's market price stood at $33.69 at the time of the reporting. The stock has advanced 232% over the past year and 117% over the last six months. An InvestingPro analysis cited by the company indicates the shares currently appear overvalued against its Fair Value estimate, placing ORKA among the most overvalued stocks tracked by that platform. The company is scheduled to report earnings in four days.
These insider moves come amid a sequence of corporate and clinical updates. Oruka reported positive interim results from its Phase 1 trial of ORKA-002, noting an extended half-life of 75-80 days. Management highlighted that such a prolonged half-life could permit less frequent dosing regimens for indications including psoriasis and hidradenitis suppurativa.
Following the Phase 1 data, Clear Street raised its price target on Oruka from $46.00 to $71.00 and maintained a Buy rating, citing the encouraging drug data. Separately, UBS initiated coverage on the company with a Buy rating and a $50.00 price target, calling attention to Oruka's position with a late-stage Phase III selective estrogen receptor degrader (SERD) in metastatic settings.
On the governance front, Oruka appointed Chris Martin to its Board of Directors after the resignation of Cameron Turtle, DPhil. Martin is described as having more than 25 years of commercial experience and most recently served as Chief Commercial Officer at Verona Pharma.
Context and significance
The combination of an insider sale executed under a pre-arranged plan and a simultaneous warrant exercise provides a clear view of the mechanics of Sandler's transactions without introducing additional company-level financial claims. The company’s recent clinical readouts and analyst actions also frame the broader investor context in which these insider transactions occurred.